Skip to main content
OpenTrials

Clinical trial condition

Urologic Diseases

Explore clinical trials studying Urologic Diseases. Study availability and eligibility vary by location and protocol.

13,603 public trials 2,148 recruiting studies
Refine in advanced search Browse all conditions

Urologic Diseases trial results

Active, Not Recruiting

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

NCT03775265

Conditions
Bladder Urothelial Carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +12 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
  • University of Arizona Cancer Center-North Campus Tucson, Arizona, United States
View all 366 locations
View Trial Details
Active, Not Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT02465060

Conditions
Adenocarcinoma, Adnexal Diseases, Advanced Lymphoma, +138 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Thomas Hospital Fairhope, Alabama, United States
  • Mobile Infirmary Medical Center Mobile, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
View all 1411 locations
View Trial Details
Active, Not Recruiting

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

NCT04640623

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, +8 more
Locations
  • Del Sol Research Management, LLC Tucson, Arizona, United States
  • University of Southern California Los Angeles, California, United States
  • Genesis Healthcare Partners - Genesis Research Greater Los Angeles Sherman Oaks, California, United States
  • The Urology Center of Colorado Denver, Colorado, United States
View all 144 locations
View Trial Details
Active, Not Recruiting

Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis

NCT05138133

Conditions
Autoimmune Diseases, Connective Tissue Diseases, Female Urogenital Diseases, +11 more
Locations
  • Research Site Glendale, Arizona, United States
  • Research Site La Palma, California, United States
  • Research Site Los Angeles, California, United States
  • Research Site Upland, California, United States
View all 164 locations
View Trial Details
Active, Not Recruiting

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

NCT05316155

Conditions
Carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +12 more
Locations
  • University of Alabama at Birmingham - The Kirklin Clinic Birmingham, Alabama, United States
  • University of Southern California Los Angeles, California, United States
  • Urology Associates of Denver Lone Tree, Colorado, United States
  • Urological Research Network Hialeah, Florida, United States
View all 59 locations
View Trial Details
Active, Not Recruiting

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

NCT04579224

Conditions
Carcinoma, Carcinoma, Transitional Cell, Female Urogenital Diseases, +17 more
Locations
  • Kingman Regional Medical Center Kingman, Arizona, United States
  • Cancer Center at Saint Joseph's Phoenix, Arizona, United States
  • Mercy Hospital Fort Smith Fort Smith, Arkansas, United States
  • CHI Saint Vincent Cancer Center Hot Springs Hot Springs, Arkansas, United States
View all 449 locations
View Trial Details
Active, Not Recruiting

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

NCT04557462

Conditions
Autoimmune Diseases, Chronic Disease, Disease Attributes, +15 more
Locations
  • AZ Kidney Dise and Hypertension Ctr Glendale, Arizona, United States
  • Kaiser Permanente San Diego, California, United States
  • North America Research Institute San Dimas, California, United States
  • University of Colorado Anschutz Aurora, Colorado, United States
View all 155 locations
View Trial Details
Active, Not Recruiting

A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease

NCT06734234

Conditions
Abnormalities, Multiple, Ciliopathies, Congenital Abnormalities, +12 more
Locations
  • GSK Investigational Site Rochester, Minnesota, United States
  • GSK Investigational Site Brussels, Belgium
  • GSK Investigational Site Ghent, Belgium
  • GSK Investigational Site Leuven, Belgium
View all 23 locations
View Trial Details
Active, Not Recruiting

Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

NCT04626518

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • University of California at San Francisco ( Site 3008) San Francisco, California, United States
  • Yale-New Haven Hospital-Yale Cancer Center ( Site 3011) New Haven, Connecticut, United States
  • University of Chicago ( Site 3013) Chicago, Illinois, United States
  • University of Iowa ( Site 3012) Iowa City, Iowa, United States
View all 51 locations
View Trial Details

Related conditions